• 海纳百川,博采众长,良药济民,大有作为
    海纳百川,博采众长,良药济民,大有作为
    Embrace all advances! Attract all talents!
    Benefit all people! Achieve all our best!
  • 做好药,中国创
    做好药,中国创
    Made in China ! Innovated in China !
  • 创新,目标,感恩,学习,团结,热爱
    创新,目标,感恩,学习,团结,热爱
    Innovation! Purpose-Driven! Gratitude! Learning! Teamwork! Passion!
  • Our Team
    Our Team

    Led by a visionary leadership team with extensive experience in top global biopharmaceutical companies, Hyperway currently has a size of over 100 employees, composed of elite young blood, mostly in their vigorous 30s, with expertise in various areas of drug discovery and development.

  • Our Specialty
    Our Specialty

    In Hyperway, we are insightful in selecting targets of novelty, druggability, and unmet clinical need, we are creative and sophisticated in designing drugs of proprietary value, we are proficient in advancing leads of efficacy and safety, we are competent in delivering CMC products of quality, and we are efficient in executing clinical development plans of thoroughness.

  • Our Focus
    Our Focus

    Hyperway is dedicated to developing First-In-Class and/or Best-In-Class small molecule drugs across cancer, pain, and autoimmune diseases. Hyperway has strategically staged our projects so that our portfolio is well-positioned with compounds in various phases of drug discovery and development to ensure a sustainable pipeline.

  • Our Platform
    Our Platform

    With our strength in designing brain-penetrant small-molecule drugs, Hyperway aims to provide the cure for those CNS-related diseases that remain in large medical needs. This platform has quickly contributed to our drug pipelines。 Hyperway is seeking partners, in China and/or abroad, to jointly develop innovative medicines.

About Hyperway
About Hyperway
Chengdu Hyperway Pharmaceuticals, a startup biotech company located in Chengdu High Tech Development Zone, was founded in January 2019 by a group of high-caliber biotech entrepreneurs and industry veterans. Hyperway, adhering to a concept of "embracing all advances, attracting all talents and benefitting all people", is committed to discovering and developing FIC and BIC new medicines to...
  • 15
    R&D pipeline
  • 30
    patent application
  • 7
    PCC
  • 4
    IND
More

Development History

Slide left to learn more
  • Jan 2019
    Chengdu Hyperway Pharmaceutical founded.
  • Angel investment completed.
    May 2019
  • Apr 2020
    Shenzhen Hyperway Pharmaceutical founded.
  • Series Pre-A financing completed.
    Apr 2020
  • Apr 2021
    Series A financing completed.
  • Clinical trial for HBW-3220 approved.
    Feb 2022
  • May 2022
    Phase Ⅰclinical trial for HBW-3220 in China launched.
  • Clinical trial for HBW-3210 approved.
    Otc 2022
  • Apr 2023
    Clinical trial for HBW-004285 approved.
  • Phase Ⅰclinical trial for HBW-3220 in China launched.
    Apr 2023

Contact:Miss Jiang

Telephone:028-87014968

Email:xiameijiang@hyperwaypharma.com

Address:8Th Floor, Building B4, Tianfu Life Science Park, No.88, Keyuan South Road, Hi-Tech Zone, Chengdu, Sichuan